Lisinopril and Kidney Stone Risk
Lisinopril is associated with a borderline decreased risk of kidney stones compared to beta-blockers, and a comparable risk to calcium channel blockers, making it a neutral to potentially protective choice regarding nephrolithiasis risk. 1
Evidence from Comparative Studies
The most direct evidence comes from a large retrospective cohort study of 542,581 adults over age 65 examining different antihypertensive classes and kidney stone risk 1:
- ACE inhibitors (including lisinopril) and ARBs showed a borderline decreased risk of kidney stones compared to beta-blockers (HR 0.90; 95% CI 0.83-0.98) 1
- Thiazide diuretics demonstrated the strongest protective effect (HR 0.76; 95% CI 0.68-0.84) compared to beta-blockers 1
- Calcium channel blockers had comparable risk to beta-blockers (HR 1.02; 95% CI 0.92-1.13) 1
When examining stones requiring intervention specifically, the protective effect of ACE inhibitors/ARBs was eliminated (HR 0.96; 95% CI 0.87-1.06), suggesting any benefit is modest and primarily for less severe stone events 1.
Clinical Context and Mechanism
The potential protective effect of ACE inhibitors like lisinopril may relate to their effects on urinary calcium excretion, though this mechanism is not as pronounced as with thiazide diuretics 1. Importantly, lisinopril's primary indications—hypertension, chronic kidney disease, and diabetic nephropathy—remain the priority considerations for prescribing 2, 3, 4, 5.
Practical Recommendations
- Lisinopril should not be avoided due to kidney stone concerns, as the evidence suggests neutral to mildly protective effects 1
- If a patient on lisinopril develops recurrent kidney stones, consider adding a thiazide diuretic if blood pressure control allows, as thiazides provide both antihypertensive benefit and stronger stone prevention 1
- Standard stone prevention measures remain essential: adequate fluid intake (targeting >2L urine output daily), dietary sodium restriction (<2g/day), and appropriate calcium intake 6, 5
Important Caveats
The protective association observed was modest and borderline significant, with the confidence interval nearly crossing 1.0 1. The study population was limited to adults over 65 years, so generalizability to younger patients is uncertain 1. The observational design cannot establish causation, only association 1.